1
|
American Cancer Society: Key statistics
for bladder cancer. https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.htmlMarch
1–2019
|
2
|
Freedman ND, Silverman DT, Hollenbeck AR,
Schatzkin A and Abnet CC: Association between smoking and risk of
bladder cancer among men and women. JAMA. 306:737–745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Pesch B, Taeger D, Johnen G, Gawrych K,
Bonberg N, Schwentner C, Wellhäusser H, Kluckert M, Leng G,
Nasterlack M, et al: Screening for bladder cancer with urinary
tumor markers in chemical workers with exposure to aromatic amines.
Int Arch Occup Environ Health. 87:715–724. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
M Babjuk M, Burger M, Zigeuner R, Shariat
S, Van Rhijn B, Compérat E, Sylvester R, Kaasinen E, Böhle A,
Palou J and Rouprêt M: Guidelines on Non-muscle-invasive Bladder
Cancer (TaT1 and CIS). http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer_LR.pdf2013.PubMed/NCBI
|
5
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and
Kurth K: Predicting recurrence and progression in individual
patients with stage Ta T1 bladder cancer using EORTC risk tables: A
combined analysis of 2596 patients from seven EORTC trials. Eur
Urol. 49:466–475. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Fernandez-Gomez J, Madero R, Solsona E,
Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa
C, Rodriguez-Molina J, et al: Predicting nonmuscle invasive bladder
cancer recurrence and progression in patients treated with bacillus
Calmette-Guerin: The CUETO scoring model. J Urol. 182:2195–2203.
2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Isharwal S and Konety B: Non-muscle
invasive bladder cancer risk stratification. Indian J Urol.
31:289–296. 2015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wozney JM, Rosen V, Celeste AJ, Mitsock
LM, Whitters MJ, Kriz RW, Hewick RM and Wang EA: Novel regulators
of bone formation: Molecular clones and activites. Science.
242:1528–1534. 1988. View Article : Google Scholar : PubMed/NCBI
|
9
|
Sampath TK, Maliakal JC, Hauschka PV,
Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM,
Pang RH, et al: Recombinant human osteogenic protein-1 (hOP-1)
induces new bone formation in vivo with a specific activity
comparable with natural bovine osteogenic protein and stimulates
osteoblast proliferation and differentiation in vitro. J Biol Chem.
267:20352–20362. 1992.PubMed/NCBI
|
10
|
Hogan BL: Bone morphogenic proteins:
Multifunctional regulators of vertebrate development. Genes Dev.
10:1580–1594. 1996. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song
W, Devereaux LM, Jin D, Sampath TK and Morton RA: Expression of
bone morphogenetic protein receptors type-IA, -IB and II correlates
with tumor grade in human prostate cancer tissues. Cancer Res.
60:2840–2844. 2000.PubMed/NCBI
|
12
|
Kim IY, Lee DH, Lee DK, Kim WJ, Kim MM,
Morton RA, Lerner SP and Kim SJ: Restoration of bone morphogenic
protein receptor type II Expression leads to a decreased rate of
tumor growth in bladder transitional cell carcinoma cell lines
TSU-Pr1. Cancer Res. 64:7355–7360. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Gou L, Liu M, Xia J, Wan Q, Jiang Y, Sun
S, Tang M, Zhou L, He T and Zhang Y: BMP9 promotes the
proliferation and migration of bladder cancer cells through
up-regulating lncRNA UCA1. Int J Mol Sci. 19(pii): E11162018.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Basic-Jukic N, Radic-Antolic M, Hudolin T,
Coric M, Zadro R, Pasini J, Kastelan Z and Kes P:
Immunolocalization and mRNA expression of bone morphogenetic
protein-6 in human clear cell renal carcinoma. Kidney Blood Press
Res. 32:445–450. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Basic-Jukic N, Hudolin T, Radic-Antolic M,
Coric M, Zadro R, Kastelan Z, Pasini J, Bandic-Pavlovic D and Kes
P: Bone morphogenetic protein-7 expression is down-regulated in
human clear cell renal carcinoma. J Nephrol. 24:91–97. 2011.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Hung TT, Wang H, Kingsley EA, Risbridger
GP and Russell PJ: Molecular profiling of bladder cancer:
Involvement of the TGF-beta pathway in bladder cancer progression.
Cancer Lett. 265:27–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Komai Y, Morimoto S, Saito K, Urushibara
M, Sakai K and Ikeda S: Possible involvement of bone morphogenetic
protein 2 in heterotopic ossification in metastatic lesion from
urothelial carcinoma of bladder. Int J Urol. 13:1126–1128. 2006.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Zaravinos A, Lambrou GI, Boulalas I,
Delakas D and Spandidos DA: Identification of common differentially
expressed genes in urinary bladder cancer. PLoS One. 6:e181352011.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Yang ZJ, Liu FX, Yang YS, Yang X and Zhu
GX: Expression of bone-morphogenetic protein 2 and tumor necrosis
factor α correlates with bone metastases in bladder urothelial
carcinoma. Ann Diagn Pathol. 17:51–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Alarmo EL, Rauta J, Kauraniemi P, Karhu R,
Kuukasjärvi T and Kallioniemi A: Bone morphogenetic protein 7 is
widely overexpressed in primary breast cancer. Genes Chromosomes
Cancer. 45:411–419. 2006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Haudenschild DR, Palmer SM, Moseley TA,
You Z and Reddi AH: Bone morphogenetic protein (BMP)-6 signaling
and BMP antagonist noggin in prostate cancer. Cancer Res.
64:8276–8284. 2004. View Article : Google Scholar : PubMed/NCBI
|
22
|
Franzen A and Heldin NE: BMP-7-induced
cell cycle arrest of anaplastic thyroid carcinoma cells via
p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun. 285:773–781.
2001. View Article : Google Scholar : PubMed/NCBI
|
23
|
Yanagita M: BMP antagonists: Their roles
in development and involvement in patophysiology. Cytokin Growth
Factor Rev. 16:309–317. 2005. View Article : Google Scholar
|
24
|
Deng H, Makizumi R, Ravikumar TS, Dong H,
Yang W and Yang WL: Bone morphogenetic protein-4 is overexpressed
in colonic adenocarcinomas and promotes migration and invasion of
HCT116 cells. Exp Cell Res. 313:1033–1044. 2007. View Article : Google Scholar : PubMed/NCBI
|
25
|
Davies SR, Watkins G, Douglas-Jones A,
Mansel RE and Jiang WG: Bone morphogenetic proteins 1 to 7 in human
breast cancer, expression pattern and clinical/prognostic
relevance. J Exp Ther Oncol. 7:327–338. 2008.PubMed/NCBI
|
26
|
Alarmo EL, Kuukasjaävi T, Karhu R and
Kallioniemi A: A comprehensive expression survey of bone
morphogenic proteins in breast cancer highlights the importance of
BMP4 and BMP7. Breast Cancer Res Treat. 103:239–246. 2007.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Autzen P, Robson CN, Bjartell A, Malcolm
AJ, Johnson MI, Neal DE and Hamdy FC: Bone morphogenic protein 6 in
skeletal metastases from prostate cancer and other common human
malignancies. Br J Cancer. 78:1219–1223. 1998. View Article : Google Scholar : PubMed/NCBI
|
28
|
Masuda H, Fukabori Y, Nakano K, Takezawa
Y, Csuzuki T and Yamanaka H: Increased expression of bone
morphogenic protein-7 in bone metastatic prostate cancer. Prostate.
54:268–274. 2003. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kim IY, Lee DH, Ahn HJ, Ahn HJ, Kim MM,
Kim SJ and Morton RA: Loss of expression of bone morphogenic
protein receptor type II in human prostate cancer cells. Oncogene.
23:7651–7659. 2004. View Article : Google Scholar : PubMed/NCBI
|
30
|
Hatakeyama S, Gao YH, Nemoto-Ohara Y,
Kataoka H and Satoh M: Expression of bone morphogenic proteins of
human neoplastic epithelial cells. Biochem Mol Biol Int.
42:497–505. 1997.PubMed/NCBI
|
31
|
Kuzaka B, Janiak M, Włodarski KH,
Radziszewski P and Włodarski PK: Expression of bone morphogenetic
protein-2 and −7 in urinary bladder cancer predicts time to tumor
recurrence. Arch Med Sci. 11:378–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
32
|
Martínez VG, Rubio C, Martínez-Fernández
M, Segovia C, López-Calderón F, Garín MI, Teijeira A,
Munera-Maravilla E, Varas A, Sacedón R, et al: BMP4 induces M2
macrophage polarization and favors tumor progression in bladder
cancer. Clin Cancer Res. 23:7388–7399. 2017. View Article : Google Scholar : PubMed/NCBI
|
33
|
Kim IY and Kim SJ: Role of bone
morphogenic proteins in transitional cell carcinoma cells. Cancer
Lett. 241:118–123. 2006. View Article : Google Scholar : PubMed/NCBI
|